Anacor Pharmaceuticals, Inc. (ANAC) Misses Q1 EPS by 12c

Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) reported Q1 EPS of ($0.51), $0.12 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $2.82 million.

“We made important progress in the first quarter on our two lead programs - Kerydin and AN2728,” said Paul Berns, President and Chief Executive Officer of Anacor Pharmaceuticals. “We have had a constructive dialogue with the FDA throughout its review of our New Drug Application for Kerydin, and we are preparing for Kerydin’s launch later this year, pending FDA approval. In addition, we recently initiated the pivotal Phase 3 studies of AN2728 for the treatment of mild-to-moderate atopic dermatitis which are continuing to enroll at sites throughout the United States.”

Cash, cash equivalents and investments totaled $146.7 million at March 31, 2014, compared to $166.8 million at December 31, 2013. Investment balances at March 31, 2014 and December 31, 2013 include short-term and long-term investments, as well as $4.2 million and $4.6 million of restricted investments, respectively.

For earnings history and earnings-related data on Anacor Pharmaceuticals, Inc. (ANAC) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• HSBC Upgrades Pegatron Corp. (4938:TT) to Hold
• Bernstein SocGen Group Downgrades Bridgestone Corp. (5108:JP) (BRDCY) to Market Perform